Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.
Corporate Profile

Exelixis, Inc. was founded and incorporated in 1994, and we are currently based in South San Francisco, California. Exelixis, from the Greek word for “evolution,” is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer.

Over the past fifteen years, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds was discovered in our own laboratories and advanced by us into clinical development.<More >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.88 (3.23%)
Data as of 07/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
07/20/17Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for CobimetinibPrinter Friendly Version
07/17/17Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017Printer Friendly Version
07/10/17Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPrinter Friendly Version
06/29/17Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of IndebtednessPrinter Friendly Version
Upcoming EventsMore >>
Q2 2017 Exelixis Inc. Financial Results Conference Call
Wednesday, August 2, 2017 5:00 p.m. ET
Add to Calendar Add Q2 2017 Exelixis Inc. Financial Results Conference Call to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2016 Annual Report (pdf)
Download Documentation2015 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.